Exploiting RUNX3-driven transcriptional networks is thus an attractive strategy to enhance CAR-T cell therapy, as accumulation within the tumour bed is imperative for CD8+ T cell-mediated tumour control. The gene discussed is CD8A; the disease is neoplasm.